摘要
一直以来,实验室研究、流行病学调查和最近的随机对照临床试验都表明阿司匹林可以降低结直肠癌的风险。出于对潜在的副作用如胃肠道出血的考虑,此前美国预防医学工作组的专家曾经建议对于处于平均风险的普通人群不要常规使用阿司匹林来预防结直肠癌。然而,最近的高质量证据表明,阿司匹林不仅可以预防结直肠癌,对其它癌症也有预防作用。因此,值得重新考虑阿司匹林是否可常规用于癌症预防这个问题。本文总结了这些支持阿司匹林化学预防功效的有力证据,认为阿司匹林广泛的抗癌效应加上它在预防心血管疾病中的作用可能推动阿司匹林在众多患者中的长期应用。
Consistent experimental, epidemiologic, and recent randomized controlled trial evidence demonstrates that aspirin lowers the risk of colorectal cancer (CRC). Prior expert bodies have recommended against the routine use of aspirin to prevent CRC in individuals at average risk, particularly in view of potential adverse consequences, including gastrointestinal bleeding. However, such recommendations preceded more recent high quality evidence of the benefit of aspirin for the prevention of not only colorectal cancer, but other cancers as well. This review summarizes this compelling body of evidence supporting the chemopreventive efficacy of aspirin. A broad anti-cancer effect of aspirin coupled with its potential role in the prevention of cardiovascular disease may tip the balance in favor of chronic aspirin use for many patients.
出处
《化学进展》
SCIE
CAS
CSCD
北大核心
2013年第9期1450-1453,共4页
Progress in Chemistry
关键词
阿司匹林
结直肠癌
随机对照试验
非阿司匹林非甾体抗炎药
化学预防
aspirin
colorectal cancer
randomized controlled trials
nonaspirin nonsteroidal anti-inflammatory drugs
chemoprevention